Although the absence of SGB-related adverse events in all included studies preliminarily suggests that SGB treatment for AP leads to fewer adverse reactions and increased safety, more high-quality evidence is required in the future to verify this conclusion. This evidence concerns the gene GPC3 and alkaline phosphatase measurement.